The Department of Health and Human Services has recommended prescribing or co-prescribing the opioid overdose reversal drug, naloxone, to high-risk patients.

The number of Americans who signed up for 2019 insurance plans created by the Affordable Care Act fell by about 4% to 8.5 million people from 2018, CMS recently announced.

The FDA has expanded the approval of a drug to now include the treatment of adults and children with recurrent, locally advanced or metastatic Merkel cell carcinoma.

Researchers recently examined the impact evolocumab plus a statin had on LDL cholesterol. 

“Effective care management for IPF should aim to improve health outcomes and reduce hospital costs,” researchers advised, “which may be achieved by the maintenance of lung function.”

The Infectious Diseases Society of America released an updated guideline on the diagnosis and treatment of seasonal influenza in patients who are at high risk for complications from the illness.

The VA has released the results of a recent customer experience survey that showed an increase in veteran trust of VA hospitals.

A recent study found that only about a quarter of older adults had advance care planning documents stating their preferences for treatment options regarding life support and instructions on who should make medical decisions on their behalf.

An advisory panel to the FDA has recommended prescribing the opioid overdose reversal drug, naloxone, along with addictive painkillers.

After demonstrating efficacy in a 6-month trial, a BP reduction intervention implemented in barbershops was further tested for sustainability through 1 year.